Molecular allergology becomes most useful when it is placed inside a clinical story. A report may contain component names and numbers, but interpretation depends on why the test was ordered, what the patient experiences, what exposures are relevant, and what decision the clinician is trying to make.

Case-based learning should teach

  • The clinical question that prompted testing.
  • The difference between sensitisation and clinical allergy.
  • How molecular patterns can support or challenge the initial hypothesis.
  • Where cross-reactivity, CCDs, and panallergens may complicate interpretation.
  • What remains uncertain and what further assessment may be needed.

Case-based learning keeps education close to practice. It allows learners to see uncertainty, competing explanations, cross-reactive patterns, and the limits of testing. This is especially important in molecular allergology, where more detailed data can either clarify or confuse depending on how it is taught.

What a good case should include

A useful case should state the clinical question, provide relevant history, show the testing pattern, highlight the interpretation challenge, and end with teaching points. It should also say what cannot be concluded from the available information.

Why cases are better than marker lists

Marker lists can be memorised without being understood. Cases force the learner to decide which information matters, which positives may be incidental, and how to communicate uncertainty responsibly.

Why this matters for MAA

MAA can build credibility by producing resources that reflect real clinical reasoning. Rather than presenting molecular testing as a product or a list of markers, the Alliance can teach how experts think through results responsibly.

Teaching point

The best molecular allergology education does not simply define components. It teaches how to ask better clinical questions.